As of Nov 19, 2026, 1 of 2 active firms rate EBS a Buy (0 Neutral, 1 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
EBS EPS & revenue forecast
EPS · NEXT QUARTER
$-0.53
Range $-0.53 – $-0.53 · 1 analysts · -857% YoY
Next period, 1 analysts expect Emergent Biosolutions Inc to earn $-0.53 a share (range $-0.53 – $-0.53), versus $0.07 a year earlier. Full-year consensus is $0.29, growing to $1.05 the year after.
REVENUE · NEXT QUARTER
$175.0M
Range $175.0M – $175.0M · 1 analysts · +12% YoY
Revenue is expected to reach $175.0M (range $175.0M – $175.0M), +12.1% year-over-year. Full-year consensus is $646.8M, rising to $703.3M next year.
Top analysts covering Emergent Biosolutions Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on EBS.
#1
Jessica Fye
JP Morgan · Rank #100
Sell
No targeton EBS
Overall win rate
54%
+ Follow
#2
RW
Robert Wasserman
Benchmark · Rank #388
Buy
$12.00+117.8% to target
Overall win rate
41%
+ Follow
#3
Raghuram Selvaraju
HC Wainwright & Co. · Rank #423
Buy
$10.00+81.5% to target
Overall win rate
36%
+ Follow
EBS stock forecast FAQ
What is EBS's average 12-month price target?+
The 1 active firms with a live target average $10.00 for Emergent Biosolutions Inc over the next 12 months, ranging from a $10.00 high to a $10.00 low, as of Nov 19, 2026.
Is EBS stock a Buy, Sell or Neutral right now?+
The current consensus is Insufficient coverage. Of the 2 active firms as of Nov 19, 2026, 1 rate it Buy or Strong Buy, 0 rate it Neutral, and 1 rate it Sell or Strong Sell.
How many active Wall Street firms cover EBS?+
2 active firms have a recognized rating on Emergent Biosolutions Inc as of Nov 19, 2026, and 1 active firms carry a live 12-month price target.
Who is the most accurate analyst covering EBS?+
Among analysts who currently cover EBS, Jessica Fye of JP Morgan has the strongest overall Quantellect track record (Rank #100). Their current call is Sell.
What is Emergent Biosolutions Inc's projected EPS for next quarter?+
The consensus estimate is $-0.53 per share (range $-0.53 – $-0.53) across 1 analysts. Full-year EPS is projected at $0.29, rising to $1.05 the following year.
How much revenue is Emergent Biosolutions Inc expected to report next quarter?+
Consensus revenue is $175.0M (range $175.0M – $175.0M). Full-year revenue is projected at $646.8M, growing to $703.3M next year.
Have analysts been upgrading or downgrading EBS lately?+
As of Nov 19, 2026, 1 of 2 active firms rate EBS a Buy (0 Neutral, 1 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their EBS calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.